EUVIMEDEUVIMED entdecken
Crossref

Efficacy of Adjuvant Chemotherapy for Stage II/III Nonsmall Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations

Takeshi Matsunaga, Kazuya Takamochi, Aritoshi Hattori, Mariko Fukui, Kenji Suzuki

The Thoracic and Cardiovascular Surgeon · 01.12.2023 · 71 (08) · 664-670

DOI: 10.1055/a-2041-3625 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Thoracic and Cardiovascular Surgeon, erschienen am 01.12.2023. Verfasst von Takeshi Matsunaga und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Thoracic Surgery, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adjuvant cisplatin-based chemotherapy improves the survival of patients with resected pathological stage II/III nonsmall cell lung cancer (NSCLC). However, the efficacy in patients with epidermal growth factor receptor (EGFR) mutations remains controversial.

Methods

This retrospective study included 353 patients with resected pathological N1/N2 stage II/III NSCLC between 2010 and 2016. Mutant EGFR (mEGFR) was detected in 76 patients. Adjuvant chemotherapy (AC) was administered to 151 patients. We compared cancer-specific survival (CSS) and recurrence-free survival (RFS) between AC and surgery-alone (SA) groups, including patients with wild-type EGFR (wEGFR) and mEGFR. Using multivariate analysis, we evaluated the prognostic factors in patients with wEGFR and mEGFR.

Results

The median follow-up time was 4.7 years. In patients with wEGFR, the differences in CSS and RFS between the AC (n = 114) and SA (n = 163) groups were significant (CSS: 66.8% [5 years] vs. 49.4% [5 years], p = 0.001; RFS: 54.2% [5 years] vs. 39.2% [5 years], p = 0.013). The significant prognostic factors were AC (vs. SA; p < 0.0001), diffusing capacity of the lung for carbon monoxide > 60% (p = 0.028), tumor size (p < 0.001), lymphatic permeation (p = 0.041), and pN1 (vs. pN2; p < 0.001). However, the differences in CSS and RFS between the AC (n = 37) and SA (n = 39) groups were not significant (CSS: 64.0% [5 years] vs. 58.1% [5 years], p = 0.065; RFS: 45.0% [5 years] vs. 33.8% [5 years], p = 0.302). Multivariate analysis identified no significant prognostic factors in patients with mEGFR.

Conclusion

We demonstrated the efficacy of AC in patients with mEGFR and wEGFR. The efficacy of AC may be lower in patients with mEGFR than in those with wEGFR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansRetrospective StudiesTreatment OutcomeNeoplasm StagingChemotherapy, AdjuvantErbB ReceptorsMutationPrognosis

Substanzen

ErbB Receptors

Autor:innen und Institutionen

  • Department of General Thoracic Surgery, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan.

Zitieren

APA

Matsunaga, T., Takamochi, K., Hattori, A., Fukui, M., & Suzuki, K. (2023). Efficacy of Adjuvant Chemotherapy for Stage II/III Nonsmall Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations. The Thoracic and Cardiovascular Surgeon, 71(08), 664-670. https://doi.org/10.1055/a-2041-3625

Vancouver

Matsunaga T, Takamochi K, Hattori A, Fukui M, Suzuki K. Efficacy of Adjuvant Chemotherapy for Stage II/III Nonsmall Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations. The Thoracic and Cardiovascular Surgeon. 2023;71(08):664-670. doi:10.1055/a-2041-3625

BibTeX
@article{Matsunaga2023,
  author = {Matsunaga, Takeshi and Takamochi, Kazuya and Hattori, Aritoshi and Fukui, Mariko and Suzuki, Kenji},
  title = {Efficacy of Adjuvant Chemotherapy for Stage II/III Nonsmall Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations},
  journal = {The Thoracic and Cardiovascular Surgeon},
  year = {2023},
  volume = {71},
  number = {08},
  pages = {664--670},
  doi = {10.1055/a-2041-3625}
}
Kostenlos starten →